About OpGen
OpGen is a company based in Rockville (United States) founded in 2002. OpGen has raised $77.51 million across 19 funding rounds from investors including European Union, 180 Degree Capital and Merck Global Health Innovation Fund. The company has 4 employees as of December 31, 2024. OpGen has completed 1 acquisition, including Curetis. OpGen offers products and services including Molecular Microbiology Services and CapForce Fintech Arm. OpGen operates in a competitive market with competitors including Prenetics, Karius, Day Zero Diagnostics, Clear Labs and Spring Bank Pharmaceuticals, among others.
- Headquarter Rockville, United States
- Employees 4 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Opgen, Inc.
-
Annual Revenue
$5.2 M (USD)52.01as on Dec 31, 2024
-
Net Profit
$11.99 M (USD)0as on Dec 31, 2024
-
EBITDA
$574.63 K (USD)0as on Dec 31, 2024
-
Total Equity Funding
$77.51 M (USD)
in 19 rounds
-
Latest Funding Round
$25 M (USD), Post-IPO
Feb 24, 2021
-
Investors
European Union
& 12 more
-
Employee Count
4
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of OpGen
OpGen is a publicly listed company on the OTC with ticker symbol OPGN in USA, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of OpGen
OpGen offers a comprehensive portfolio of products and services, including Molecular Microbiology Services and CapForce Fintech Arm.
Offers solutions to combat antimicrobial resistance using advanced techniques.
Provides financial technology solutions as a new business expansion.
People of OpGen
Unlock access to complete
Unlock access to complete
Funding Insights of OpGen
OpGen has successfully raised a total of $77.51M across 19 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OpGen
OpGen has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, 180 Degree Capital and Merck Global Health Innovation Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Corporate-backed venture capital is focused on the life science sector.
|
Locked | Locked | Locked | |
|
Venture capital investment and entrepreneur support services.
|
Locked | Locked | Locked | |
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Locked | Locked | Locked |
Investor details for OpGen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OpGen
OpGen has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Curetis.
Investment portfolio details for OpGen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Molecular diagnostics platform is provided for infectious disease detection.
|
Locked | Locked | 2007 | Locked |
Complete acquisition details for OpGen
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - OpGen
Detailed financials for OpGen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Opgen Comparisons
Peer comparison for OpGen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OpGen
OpGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Prenetics, Karius, Day Zero Diagnostics, Clear Labs and Spring Bank Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
|
| Locked | Locked | Locked |
Developer of a non-invasive pathogen blood test for the detection of infectious diseases
|
|
| Locked | Locked | Locked |
Genome sequencing diagnostics for infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Food safety technologies are provided for pathogen identification.
|
|
| Locked | Locked | Locked |
Viral infection treatments are developed using nucleic acid hybrid chemistry.
|
Detailed competitors of OpGen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Opgen
Complete news archive for OpGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OpGen
OpGen was founded in 2002 and raised its 1st funding round 3 years after it was founded.
OpGen is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Oliver Schacht is the current CEO of OpGen.
OpGen is a funded company, having raised a total of $77.51M across 19 funding rounds to date.
As of Dec 31, 2024, the latest employee count at OpGen is 4.
Annual revenue of OpGen is $5.2M as on Dec 31, 2024.
Founded in 2002 and headquartered in Rockville, United States, OpGen operates in the diagnostics and bioinformatics sector. Platforms and tests, including the Acuitas MDRO Gene Test, Acuitas Lighthouse MDRO Management System, and Acuitas Resistome Test, are provided to healthcare providers. These tools support the detection of multi-drug resistant organisms in hospital patients, aiding infection management efforts.
OpGen's top competitors include Prenetics, Clear Labs and Day Zero Diagnostics.
OpGen offers Molecular Microbiology Services and CapForce Fintech Arm.
Yes, OpGen is publicly traded on OTC under the ticker symbol OPGN.
OpGen has made 1 acquisition, including Curetis.
OpGen has 13 investors. Key investors include European Union, 180 Degree Capital, Merck Global Health Innovation Fund, Highland Capital Partners, and Versant Ventures.
The ticker symbol of OpGen is OPGN on OTC.